Bausch Health Cos Income After Taxes 2010-2024 | BHC

Bausch Health Cos income after taxes from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Bausch Health Cos Annual Income After Taxes
(Millions of US $)
2023 $-611
2022 $-212
2021 $-937
2020 $-559
2019 $-1,783
2018 $-4,144
2017 $2,404
2016 $-2,408
2015 $-288
2014 $880
2013 $-864
2012 $-116
2011 $160
2010 $-208
2009 $176
Bausch Health Cos Quarterly Income After Taxes
(Millions of US $)
2024-09-30 $-92
2024-06-30 $-1
2024-03-31 $-77
2023-12-31 $-47
2023-09-30 $-382
2023-06-30 $27
2023-03-31 $-209
2022-12-31 $-410
2022-09-30 $403
2022-06-30 $-139
2022-03-31 $-66
2021-12-31 $72
2021-09-30 $191
2021-06-30 $-593
2021-03-31 $-607
2020-12-31 $-152
2020-09-30 $70
2020-06-30 $-325
2020-03-31 $-152
2019-12-31 $-1,517
2019-09-30 $-48
2019-06-30 $-170
2019-03-31 $-48
2018-12-31 $-342
2018-09-30 $-351
2018-06-30 $-872
2018-03-31 $-2,579
2017-12-31 $512
2017-09-30 $1,300
2017-06-30 $-37
2017-03-31 $629
2016-12-31 $-512
2016-09-30 $-1,219
2016-06-30 $-304
2016-03-31 $-373
2015-12-31 $-387
2015-09-30 $52
2015-06-30 $-52
2015-03-31 $99
2014-12-31 $502
2014-09-30 $276
2014-06-30 $122
2014-03-31 $-20
2013-12-31 $125
2013-09-30 $-972
2013-06-30 $11
2013-03-31 $-28
2012-12-31 $-89
2012-09-30 $8
2012-06-30 $-22
2012-03-31 $-13
2011-12-31 $56
2011-09-30 $41
2011-06-30 $56
2011-03-31 $6
2010-12-31 $-31
2010-09-30 $-208
2010-06-30 $34
2010-03-31 $-3
2009-12-31 $73
2009-09-30 $40
2009-06-30 $24
2009-03-31 $39
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $3.012B $8.757B
Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00